NasdaqGS - Delayed Quote • USD
Sanofi (SNY)
At close: April 25 at 4:00 PM EDT
Pre-Market: 8:27 AM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 4 | 4 |
| Avg. Estimate | 0.94 | 0.93 | 4.16 | 4.82 |
| Low Estimate | 0.94 | 0.93 | 4.07 | 4.75 |
| High Estimate | 0.94 | 0.93 | 4.25 | 4.93 |
| Year Ago EPS | 1.16 | 0.95 | 4.38 | 4.16 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 5 | 16 | 16 |
| Avg. Estimate | 11.1B | 11.31B | 50.07B | 53.5B |
| Low Estimate | 10.81B | 11.1B | 47.68B | 50.45B |
| High Estimate | 11.68B | 11.71B | 53.21B | 57.05B |
| Year Ago Sales | 11.33B | 11.23B | 46.57B | 50.07B |
| Sales Growth (year/est) | -2.00% | 0.70% | 7.50% | 6.80% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 1.1 | 0.89 | 1.37 | 0.91 |
| EPS Actual | 1.16 | 0.95 | 2.77 | 0.89 |
| Difference | 0.06 | 0.06 | 1.4 | -0.02 |
| Surprise % | 5.50% | 6.70% | 102.20% | -2.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.94 | 0.93 | 4.16 | 4.82 |
| 7 Days Ago | 1.92 | 1.8 | 4.21 | 4.85 |
| 30 Days Ago | 1.92 | 1.8 | 4.23 | 4.97 |
| 60 Days Ago | 1.91 | 1.79 | 7.77 | 9.25 |
| 90 Days Ago | 0 | 0 | 7.47 | 8.92 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | 2 | 1 |
Growth Estimates
| CURRENCY IN USD | SNY | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -19.00% | -- | -- | 2.60% |
| Next Qtr. | -2.10% | -- | -- | 13.40% |
| Current Year | -5.00% | -- | -- | 5.20% |
| Next Year | 15.90% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 9.00% | -- | -- | 11.11% |
| Past 5 Years (per annum) | 13.18% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Initiated | Morgan Stanley: Equal-Weight | 1/23/2024 |
| Maintains | Argus Research: Buy | 3/27/2023 |
| Upgrade | Deutsche Bank: Sell to Hold | 8/12/2022 |
| Upgrade | SVB Leerink: Market Perform to Outperform | 9/27/2021 |
| Initiated | Deutsche Bank: Sell | 1/15/2021 |
| Upgrade | Goldman Sachs: Neutral to Buy | 3/11/2020 |
Related Tickers
AZN AstraZeneca PLC
75.03
+5.38%
NVS Novartis AG
99.06
+0.72%
GSK GSK plc
40.91
+0.12%
RHHBY Roche Holding AG
30.02
-1.70%
BMY Bristol-Myers Squibb Company
44.70
-8.51%
GILD Gilead Sciences, Inc.
65.27
-2.70%
MRK Merck & Co., Inc.
130.72
+2.93%
BIIB Biogen Inc.
202.46
+0.23%
AMGN Amgen Inc.
269.38
-1.33%
OGN Organon & Co.
18.42
-1.55%